For more information, visit our Nephrology Program
Return to Non-Cancer Program Name Search
Title: A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
Brief Title: Efficacy and Safety of VX-407 in Subjects with ADPKD
Brief Summary: The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total
kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
For info regarding 2025P000876
please contact Colton Wright at 617-975-8692 or
cwrigh14@bidmc.harvard.edu
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Brief Title: Study of ABBV-CLS-628 in Adults with ADPKD
Brief Summary: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of
kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of
this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of
ADPKD in adult participants.
ABBV-CLS-628 is an investigational drug being developed for the treatment of ADPKD.
Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a
different treatment. There is a 1 in 4 chance that participants will be assigned to
placebo. Around 240 adult participants with ADPKD will be enrolled at approximately 100
sites worldwide.
Participants will receive IntraVenous ABBV-CLS-628 or placebo every 4 weeks for 92 weeks.
Participants will be followed for up to 15 weeks.
There may be higher treatment burden for participants in this trial compared to their
standard of care . Participants will attend regular visits during the study at a hospital
or clinic. The effect of the treatment will be checked by medical assessments, blood
tests, checking for side effects and completing questionnaires.
For info regarding 2025P000270
please contact Peter Czarnecki at 617-667-8378 or
pczarnec@bidmc.harvard.edu
Title: Development of a clinical experimental heat stress protocol and exploration of the effect of Niacinamide on physiologic, metabolic, and biochemical responses to heat stress
Brief Title: Experimental heat stress metabolomics and the effect of Nam
Brief Summary: The goal of this clinical trial is to learn about the processes occurring in the kidneys
while under heat stress in healthy volunteers. The main questions it aims to answer are:
- How do the chemicals produced by the body change under conditions of higher versus
lower heat stress?
- What role does a specific area of the body's metabolism, known as NAD+ metabolism,
play in the body's response to heat stress, and can this response be modified by
taking vitamin B3?
For info regarding 2024P000637
please contact Nathan Raines at 617-632-9880 or
nraines@bidmc.harvard.edu
Title: A Phase 2/3 Adaptive, Double-blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adults and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
Brief Title: Phase 2/3 Adaptive Study of VX-147 in Adults With APOL1-medi
Brief Summary: The purpose of this study is to evaluate the efficacy, safety, tolerability, and
pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein
L1 (APOL1)-mediated proteinuric kidney disease.
For info regarding 2022P000526
please contact Liz Roy at (617) 975-8684 or
eroy2@bidmc.harvard.edu